Self Efficacy, Walking Ability, Gait Speed and Physical Activity in People With Chronic Lung Disease

Chronic Lung Disease Clinical Trial

Official title:

Determining the Relationships Between Self-efficacy for Walking Ability, Gate Speed and Physical Activity in Patients With Chronic Lung Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01583595
• Other study ID #: 11-008157
• Status: Completed
• Phase: N/A
• First received: February 7, 2012
• Last updated: April 1, 2013
• Start date: December 2011
• Est. completion date: July 2012

Study information

• Verified date: March 2013
• Source: Mayo Clinic
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Most patients with chronic lung disease underestimate their actual walking ability due to low confidence. To better understand the relationships between lung function, self-efficacy for walking (confidence in ability to walk a defined distance), actual walking ability for the same distance gait speed and physical activity level-PAL- (total energy expenditure/resting metabolic rate).

Quality of life, self efficacy for activity questionnaires, physical activity level measurement, 4-meter gait speed and 6-minute walk distance will be measured.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: July 2012
• Est. primary completion date: July 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Men and women 40 years and older

• Diagnosis of any chronic lung disease as evidenced by pulmonary function testing completed within the prior 12 months

• Able to walk independently and successfully complete the 6-minute walk assessment

Exclusion Criteria:

• Unable to walk without assistance or complete the 6-minute walk assessment

• Patients unable to comprehend and accurately respond to the study questionnaires either by written or spoken communication

• Patients diagnosed with or treated for a lower respiratory tract infection or COPD exacerbation within the prior 30 days

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Chronic Lung Disease
• Lung Diseases
• Self-efficacy

Locations

Country	Name	City	State
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Analyze associations between self-efficacy for walking, gait speed, physical activity level and perceptions of symptoms in patient with chronic lung disease (COPD and Pulmonary Fibrosis)	Correlation , regression models and mediation analysis (self efficacy and physical activity) will be performed.	Day of enrollment.	No
Secondary	Predictive utility of 4-meter gait speed for estimating physical activity level (PAL) as validated by gold standard activity monitor.	Measure 4-meter gait speed during standardized 6 mintute walk test and compare to armband activity monitor results to determine predictive ability, if any, on PAL in people with chronic lung disease.	1 week	No